Simcere's diosmectite API passes EU-GMP inspection

Published: 22-Apr-2010
Ingredients Research & Development Pharmaceutical

Active pharmaceutical ingredient in Biqi cleared for direct sale to EU countries


Chinese pharmaceutical company Simcere Pharmaceutical Group has announced that its diosmectite, the active pharmaceutical ingredient in its branded generic drug Biqi, has passed EU-GMP inspection. This enables Simcere to market diosmectite in the EU.

Simcere has been manufacturing and marketing diosmectite API and formulation under the Biqi brand name for many years in China. Diosmectite is made from a natural mineral material and its formulation is the leading antidiarrhoeal drug in China and France. Simcere owns a high grade diosmectite mine in China.

‘We are delighted that Simcere's diosmectite has passed EU-GMP inspection and been approved for sale in the EU,’ said Jinsheng Ren, chairman and ceo of Simcere Pharmaceutical Group. ‘This is an important start in driving our international business.’
  • Companies:
  • Simcere Pharmaceutical Group
See more

You may also like

Finance

Chinese drug majors look to the West to build brands

Read more
In China, large drug manufacturers are seeking partnerships, mergers and acquisitions with Western companies, writes Asia correspondent A Nair

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Finance

Chinese drug majors look to the West to build brands

In China, large drug manufacturers are seeking partnerships, mergers and acquisitions with Western companies, writes Asia correspondent A Nair
Research & Development

Bristol-Myers Squibb announces second pact with Simcere

The firms will co-develop BMS-795311, a preclinical small molecule CETO inhibitor
Finance

Merck and Simcere agree joint venture

Will initially offer drugs for cardiovascular and metabolic diseases
Manufacturing

Chinese vaccine manufacturer fined for substandard product

Penalty in addition to previous fine imposed six months ago
Research & Development

Bristol-Myers Squibb enters partnership with Simcere

Will co-develop a preclinical cancer compound
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Manufacturing

Rapid increase in purchasing teams expected at CPHI North America

Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Subscribe now